A68828 | CAS# 132309-52-5 | Atrial natriuretic factor

MedKoo Cat#: 571270 | Name: A 68828

Description:

WARNING: This product is for research use only, not for human or veterinary use.

A 68828 is an atrial natriuretic factor analog. It improves renal function and reduces tissue damage.

Chemical Structure

A 68828

CAS#13209-52-5

Theoretical Analysis

MedKoo Cat#: 571270

Name: A 68828

CAS#: 13209-52-5

Chemical Formula: C68H116N26O15S2

Exact Mass: 1600.8555

Molecular Weight: 1601.96

Elemental Analysis: C, 50.98; H, 7.30; N, 22.73; O, 14.98; S, 4.00

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

A 68828; A-68828; A68828

IUPAC/Chemical Name

(6S,9R,13R,16S,19S,22S,25S,28S)-1,6-diamino-28-((2S,5S,14S,Z)-14-amino-2-((S)-sec-butyl)-15-cyclohexyl-5-(3-guanidinopropyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazapentadec-11-enamido)-19-benzyl-22-((S)-sec-butyl)-16,25-bis(3-guanidinopropyl)-1-imino-9,13-bis(mercaptomethyl)-7,10,12,15,18,21,24,27-octaoxo-2,8,11,14,17,20,23,26-octaazatriacontan-30-oic acid

InChi Key

HCJNLCHEKMAIHX-PVCRQNKGSA-N

InChi Code

InChI=1S/C68H116N26O15S2/c1-5-36(3)52(63(108)88-45(30-39-19-11-8-12-20-39)59(104)86-43(23-15-27-81-67(75)76)56(101)91-48(35-111)62(107)94-61(106)47(34-110)90-55(100)40(69)21-13-25-79-65(71)72)93-58(103)44(24-16-28-82-68(77)78)87-60(105)46(31-51(97)98)89-64(109)53(37(4)6-2)92-57(102)42(22-14-26-80-66(73)74)85-50(96)33-83-49(95)32-84-54(99)41(70)29-38-17-9-7-10-18-38/h8,11-12,19-20,32,36-38,40-48,52-53,110-111H,5-7,9-10,13-18,21-31,33-35,69-70H2,1-4H3,(H,83,95)(H,85,96)(H,86,104)(H,87,105)(H,88,108)(H,89,109)(H,90,100)(H,91,101)(H,92,102)(H,93,103)(H,97,98)(H4,71,72,79)(H4,73,74,80)(H4,75,76,81)(H4,77,78,82)(H,94,106,107)/b84-32-/t36-,37-,40-,41-,42-,43-,44-,45-,46-,47-,48-,52-,53-/m0/s1

SMILES Code

CC[C@@H]([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC(/C=N\C([C@@H](N)CC1CCCCC1)=O)=O)=O)CCCNC(N)=N)=O)[C@H](CC)C)=O)CC(O)=O)=O)CCCNC(N)=N)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(NC([C@@H](NC([C@@H](N)CCCNC(N)=N)=O)CS)=O)=O)CS)=O)CCCNC(N)=N)=O)CC2=CC=CC=C2)=O)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,601.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Pollock DM, Opgenorth TJ. Beneficial effect of the atrial natriuretic factor analog A68828 in postischemic acute renal failure. J Pharmacol Exp Ther. 1990 Dec;255(3):1166-9. PubMed PMID: 2148187. 2: Pollock DM, Opgenorth TJ. Beneficial effect of the ANF analog A68828 on recovery from ischemic acute renal failure. Ren Fail. 1992;14(2):141-6. PubMed PMID: 1386156. 3: Deegan PM, Ryan MP, Basinger MA, Jones MM, Hande KR. Protection from cisplatin nephrotoxicity by A68828, an atrial natriuretic peptide. Ren Fail. 1995 Mar;17(2):117-23. PubMed PMID: 7644762. 4: Pollock DM, Holst M, Opgenorth TJ. Effect of the ANF analog A68828 in cisplatin-induced acute renal failure. J Pharmacol Exp Ther. 1991 Jun;257(3):1179-83. PubMed PMID: 1828504. 5: Devine EM Jr, Buko AM, Cepa SP, Davidsen SK, Holleman WH, Marselle CA, Opgenorth TJ, Rockway TW, von Geldern TW. HPLC and PDMS analysis of cleavage products aid in the design of small, stable ANP analogues. Int J Pept Protein Res. 1992 Dec;40(6):532-7. PubMed PMID: 1286937. 6: von Geldern TW, Rockway TW, Davidsen SK, Budzik GP, Bush EN, Chu-Moyer MY, Devine EM Jr, Holleman WH, Johnson MC, Lucas SD, et al. Small atrial natriuretic peptide analogues: design, synthesis, and structural requirements for guanylate cyclase activation. J Med Chem. 1992 Mar 6;35(5):808-16. PubMed PMID: 1347790. 7: Pollock DM, Opgenorth TJ. Atrial natriuretic peptides in the treatment of acute renal failure. Ren Fail. 1993;15(4):439-49. Review. PubMed PMID: 8210557. 8: Holleman WH, Budzik GP, Devine EM, Pollock DM, Opgenorth TJ, Thomas AM, von Geldern TW, Rockway TW. Truncated atrial natriuretic factor analogs retain full agonist activity. Can J Physiol Pharmacol. 1991 Oct;69(10):1622-7. PubMed PMID: 1663820.